Comparative tissue factor pathway inhibitor release potential of heparins

Area of Science:

• Pharmacology
• Hematology
• Biochemistry

Background:

• Tissue factor pathway inhibitor (TFPI) is crucial in regulating the coagulation cascade.
• TFPI release can be induced by various anticoagulants, including unfractionated heparin and low-molecular-weight heparins.
• Understanding TFPI release mechanisms is vital for anticoagulant therapy optimization.

Purpose of the Study:

• To compare the effects of heparin, gammaparin (a low-molecular-weight heparin), and subeparin (C3, a heparin-derived oligosaccharide mixture) on TFPI activity.
• To investigate the dose-dependent and route-dependent (intravenous vs. subcutaneous) TFPI release in a non-human primate model.
• To explore factors influencing TFPI release, such as molecular weight and charge density.

Main Methods:

• Administration of heparin, gammaparin, and C3 at 1 mg/kg to Macaca mulatta primates.
• Measurement of functional and immunologic TFPI activity levels at baseline and at 5 minutes post-administration.
• Analysis of dose-dependent effects following intravenous and subcutaneous administration routes.

Main Results:

• Both heparin and gammaparin significantly increased functional TFPI levels to 2.40 and 2.56 U/mL, respectively, and immunologic TFPI levels by 4.3- and 4.0-fold.
• Subeparin (C3) resulted in lower increases in functional (1.08 U/mL) and immunologic (2.1-fold) TFPI levels compared to heparin and gammaparin.
• TFPI release was observed to be dose-dependent and influenced by the route of administration.

Conclusions:

• Heparin and gammaparin exhibit similar potential for TFPI release, suggesting molecular weight may not be the sole determinant.
• Gammaparin represents a viable alternative to heparin regarding TFPI release effects.
• Further research is warranted to elucidate the roles of charge density and interactions with heparin cofactor II in TFPI release.